This review summarises the characteristics of rituximab and other anti-CD20 monoclonal antibodys for NHL treatment.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
*Letizia Polito, Massimo Bortolotti, Stefania Maiello, Maria Giulia Battelli, Andrea Bolognesi
Department of Experimental, Diagnostic, and Specialty Medicine – DIMES, Alma Mater Studiorum – University of Bologna, Bologna, Italy
*Correspondence to letizia.polito@unibo.it
Disclosure: No potential conflict of interest.
Received: 01.04.14 Accepted: 18.06.14
Citation: EMJ Oncol. 2014;2:63-69.